Roche Holding AG (SWX:ROG) agreed to acquire Tib Molbiol on September 9, 2021. Closing of the transaction is subject to customary conditions and is expected in the fourth quarter of 2021. With over 45 CE-IVD assays and more than a 100 research-use-only assays joining the Roche family. TIB Molbiol will continue to operate as a subsidiary within the Diagnostics division. TIB Molbiol founder and CEO Olfert Landt was advised by Kai-Steffen Scholz and Alexander Bekier of law firm Hengeler Mueller Partnerschaft von RechtsanwÃ¤lten mbB. Roche group senior counsel for M&A, Structure and Finance, Ruben Perren, and head of legal for Asia Pacific, Felix Kobel, acted as lead counsel for the buyer. They were advised by a Gleiss Lutz Hootz Hirsch PartmbB team, led by Alexander Schwarz and Martin Viciano Gofferje.
Roche Holding AG (SWX:ROG) completed the acquisition of Tib Molbiol on December 31, 2021. Kai Fischer of Cuatrecasas, Gonçalves Pereira, S.L.P. acted as legal advisor for Roche.